Early increase of von willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin

Circulation

Volumn 98, Issue 4, 1998, Pages 294-299

  Montalescot, Gilles ^a   Philippe, François ^a   Ankri, Annick ^a   Vicaut, Eric ^b   Bearez, Etienne ^c   Poulard, Jean Ernest ^d   Carrie, Didier ^e   Flammang, Daniel ^f   Dutoit, Albert ^g   Carayon, Alain ^a   Jardel, Claude ^a   Chevrot, Monique ^a   Bastard, Jean Philippe ^a   Bigonzi, Fredérique ^h   Thomas, Daniel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL FERNAND WIDAL   (France)

^c Arras Hospital   (France)

^d Abbeville Hospital   (France)

^e CHU PURPAN   (France)

^f Angouleme General Hospital   (France)

^g Centre Hospitalier Saint Philibert GHICL   (France)

^h SANOFI   (France)

Author keywords

C reactive protein; Coronary disease; Fibrinogen; Heparin; Von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; ENOXAPARIN; FIBRINOGEN; HEPARIN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032575359     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.4.294     Document Type: Article

References (40)

1. Roberts R, Kleiman NS. Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a "new diagnostic mind-set." Circulation. 1994;8:872-881.
2. Antman EL, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
3. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE, Califf RM, Topol EJ, for the GUSTO-IIa Investigators. Cardiac troponin T levels for risk stratification in acute myocardial infarction. N Engl J Med. 1996;335:1333-1341.
4. Lindahl B, Venge P, Wallentin L, for the FRISC Study Group. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation. 1996;93:1651-1657.
5. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol. 1990;65:168-172.
6. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
7. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Galigiuri G, Lanea GA, Monaco C, Pepys MB, Maseri A. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2373-2380.
8. Toss H, Lindahl B, Siegbahn A, Wellentin L, for the FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96:4204-4210.
9. Andreotti F, Roncaglioni C, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol. 1990;16:1553-1560.
10. Cucuianu MP, Missits I, Olinic N, Roman S. Increased ristocetin-cofactor in acute myocardial infarction: a component of the acute phase reaction. Thromb Haemost. 1980;43:41-44.
11. Margulis T, David M, Maor N. The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemost. 1986; 55:366-368.
12. Mossard JM, Wiesel ML, Cazenave JP, Grunebaum L, Drawin T, Kieny JR, Roul G, Bareiss P, Sacrez A. Relations entre augmentation du facteur de Willebrand plasmatique, infarctus du myocarde aigu, angor instable et thrombose coronaire. Arch Mal Coeur. 1989;82:1813-1818.
13. al-Nozha M, Gader AM, al-Momen AK, Noah MS, Jawaid M, Arafa M. Haemostatic variables in patients with unstable angina. Int J Cardiol. 1994;43:269-277.
14. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31-38.
15. Yazdani S, Simon A, Kovar L, Wang W, Schwartz A, Rabbani LE. Percutaneous interventions alter the hemostatic profile of patients with unstable angina. J Am Coll Cardiol. 1997;30:1284-1287.
16. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:1102-1108.
17. Montalescot G, Viossat I, Chabrier PE, Sotirov I, Detienne JP, Drobinski G, Frank R, Grosgogeat Y, Thomas D. Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization. J Am Coll Cardiol. 1994;24:1236-1241.
18. Stewart DJ, Kubac J, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
19. Ray SG, McMurray JJ, Morton JJ, Dargie HJ. Circulating endothelin in acute ischaemic syndromes. Br Heart J. 1992;67:383-386.
20. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:53-54.
21. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, for the ESSENCE Study Group. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
22. Clauss A. Gerinnungsphysiologishe Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
23. Cacoub P, Dorent R, Maistre, Nataf P, Carayon A, Piette JC, Godeau P, Cabrol C, Gangjbakhch I. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol. 1993;71:448-450.
24. Dixon WJ, ed. BMDP Statistical Software. Berkeley, Calif: University of California Press; 1985.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
26. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
27. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991;88:1568-1573.
28. Ruggeri ZM. von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992;86(suppl III):III-26-III-29.
29. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood, I: shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med. 1978;92:750-764.
30. Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost. 1993;70:99-104.
31. Sobel M, McNeill PM, Carlson P, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
32. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem. 1992;267:8857-8862.
33. Sobel M, Bird KE, Tyler-Cross R, Marques D, Toma N, Conrad E, Harris RB. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation. 1996;93:992-999.
34. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem. 1986;261:3980-3986.
35. Zammit A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost. 1993;70:951-958.
36. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.
37. Fays PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem. 1991;266:2172-2177.
38. Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefell WE, Krulthof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels. Thromb Haemost. 1997;77:387-393.
39. Beguin S, Mardiguian J, Lindhout T, Hemker HC. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost. 1989;61:30-34.
40. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res. 1993;69:443-452.